Related references
Note: Only part of the references are listed.Targeting the Integrated Stress Response in Cancer Therapy
Xiaobing Tian et al.
FRONTIERS IN PHARMACOLOGY (2021)
Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells
Timo Burster et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors
Michael H. Meel et al.
NEURO-ONCOLOGY (2020)
Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children's Oncology Group Trial ACNS0333
Alyssa T. Reddy et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus
Ben Ho et al.
NEURO-ONCOLOGY (2020)
MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors
Shubin Shahab et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2020)
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Martin H. Voss et al.
BRITISH JOURNAL OF CANCER (2020)
Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo
Irina Alimova et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin
Brad Poore et al.
NEURO-ONCOLOGY (2019)
The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
Franziska M. Ippen et al.
CLINICAL CANCER RESEARCH (2019)
Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor
Yukinori Terada et al.
CELL REPORTS (2019)
Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Sabrina Z. Wang et al.
CLINICAL CANCER RESEARCH (2019)
Targeting mTOR for cancer therapy
Hui Hua et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression
Feven Tameire et al.
NATURE CELL BIOLOGY (2019)
Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation
Serap Erkek et al.
CANCER CELL (2019)
NRF2 and the Hallmarks of Cancer
Montserrat Rojo de la Vega et al.
CANCER CELL (2018)
Glutathione metabolism in cancer progression and treatment resistance
Ankita Bansal et al.
JOURNAL OF CELL BIOLOGY (2018)
The Unfolded Protein Response and Cell Fate Control
Claudio Hetz et al.
MOLECULAR CELL (2018)
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E. Tron et al.
NATURE COMMUNICATIONS (2018)
mTOR signalling and cellular metabolism are mutual determinants in cancer
Dirk Mossmann et al.
NATURE REVIEWS CANCER (2018)
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
Kathleen N. Moore et al.
ESMO OPEN (2018)
BCL-2 family proteins: changing partners in the dance towards death
Justin Kale et al.
CELL DEATH AND DIFFERENTIATION (2018)
The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity
Jeffrey A. Rubens et al.
NEURO-ONCOLOGY (2017)
WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit
Jing Wang et al.
NUCLEIC ACIDS RESEARCH (2017)
BCL-2 family: integrating stress responses at the ER to control cell demise
Philippe Pihan et al.
CELL DEATH AND DIFFERENTIATION (2017)
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Howard A. Burris et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
The integrated stress response and proteotoxicity in cancer therapy
David J. McConkey
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's macroglobulinemia
Irene M. Ghobrial et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors
Jonathon Torchia et al.
CANCER CELL (2016)
Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes
Pascal D. Johann et al.
CANCER CELL (2016)
The integrated stress response
Karolina Pakos-Zebrucka et al.
EMBO REPORTS (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies
Michael C. Fruehwald et al.
NEURO-ONCOLOGY (2016)
The Dual Roles of NRF2 in Cancer
Silvia Menegon et al.
TRENDS IN MOLECULAR MEDICINE (2016)
The Chromatin-Modifying Protein HMGA2 Promotes Atypical Teratoid/Rhabdoid Cell Tumorigenicity
Harpreet Kaur et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2015)
The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest
Manuel D. Haschka et al.
NATURE COMMUNICATIONS (2015)
Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target
Melanie F. Weingart et al.
ONCOTARGET (2015)
SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis
Martin Hasselblatt et al.
ACTA NEUROPATHOLOGICA (2014)
PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Anat Erdreich-Epstein et al.
CLINICAL CANCER RESEARCH (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Nrf2, a Regulator of the Proteasome, Controls Self-Renewal and Pluripotency in Human Embryonic Stem Cells
Jiwon Jang et al.
STEM CELLS (2014)
Nrf2 is required to maintain the self-renewal of glioma stem cells
Jianhong Zhu et al.
BMC CANCER (2013)
A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies
Jeffrey R. Infante et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma
Erika F. Rodriguez et al.
ACTA NEUROPATHOLOGICA (2011)
mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets
Ryosuke Watanabe et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing
Min H. Kang et al.
PEDIATRIC BLOOD & CANCER (2011)
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies
Paul K. Paik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma
Jimmy J. Hwang et al.
CLINICAL CANCER RESEARCH (2010)
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2009)
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2009)
Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress
Chen Chen Jiang et al.
CANCER RESEARCH (2008)
Targeting the PI3K p110α Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration
Ana S. Guerreiro et al.
CLINICAL CANCER RESEARCH (2008)
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo
Dolores Hambardzumyan et al.
GENES & DEVELOPMENT (2008)
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis
Mai Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Novel role for insulin as an autocrine growth factor for malignant brain tumour cells
Alexandre Arcaro et al.
BIOCHEMICAL JOURNAL (2007)
Coordination of ER and oxidative stress signaling: The PERK/Nrf2 signaling pathway
SB Cullinan et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2006)
Share Paper
